A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.

PURPOSE: In preclinical models, radioimmunotherapy with (131)I-A5B7 anti-carcinoembryonic antigen (CEA) antibody ((131)I-A5B7) combined with the vascular disruptive agent combretastatin-A4-phosphate (CA4P) produced cures unlike either agent alone. We conducted a phase I trial determining the dose-l...

Full description

Bibliographic Details
Main Authors: Meyer, T, Gaya, A, Dancey, G, Stratford, MR, Othman, S, Sharma, S, Wellsted, D, Taylor, N, Stirling, J, Poupard, L, Folkes, L, Chan, P, Pedley, R, Chester, K, Owen, K, Violet, J, Malaroda, A, Green, A, Buscombe, J, Padhani, A, Rustin, G, Begent, R
Format: Journal article
Language:English
Published: 2009

Similar Items